Imugene Limited (ASX:IMU) preclinical research related to HER-Vaxx (clinical name IMU-131) has been accepted and published in the prestigious journal BMC Cancer. IMU-131 is a next generation HER-2 cancer therapy using B cell peptides, which harness the body's ability to develop antibodies against the disease.
Imugene Limited (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.
HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target. HER-Vaxx's successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016.
Australian and New Zealand biotech investors are set to hear from a top line up of speakers from ASX-listed life science companies, as well as several private firms and international businesses, in July, at the 11th Bioshares Biotech Summit.
Australian Market Report of September 16, 2010: Conquest Mining Limited (ASX:CQT) Enters Into Gold-Silver-Copper Offtake Contract with Shandong Guoda Gold
Australian Market Report of September 16, 2010 inclues; Conquest Mining (ASX:CQT) has entered into an offtake contract for the sale of gold-silver-copper concentrate from its V2 deposit at Mt Carlton, Heemskirk Consolidated Limited (ASX:HSK) has announced the signing of an agreement with Conquest Mining Limited (ASX:CQT), Imugene Limited (ASX:IMU) today announced it has successfully completed a second trial of its Porcine Reproductive and Respiratory Syndrome (PRRS) vaccine and Synthesis Energy Systems Inc. (NASDAQ:SYMX) and Coalworks Limited (ASX:CWK) today made a joint presentation titled "Production of Liquid Fuels from Oaklands Coal Utilizing U-GAS(R) and MTG Technologies".
IMUGENE LIMITED Biotech Forum<br/>The Road to Commercialisation; Boardroomradio is pleased to announce that IMUGENE LIMITED (ASX: IMU) has published an audio file. The following presentation "" is now